`571-272-7822
`
`
`
` Paper No. 72
` Entered: March 28, 2019
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`________________
`
`MYLAN PHARMACEUTICIALS INC. and
`DR. REDDY’S LABORATORIES, INC.,
`Petitioners,
`v.
`HORIZON PHARMA USA, INC. and NUVO PHARMACEUTICALS
`(IRELAND) DESIGNATIVED ACTIVITY COMPANY,
`Patent Owners.
`_________________
`
`Cases
`IPR2017-019951,2 (Patent 9,220,698 B2)
`IPR2018-00272 (Patent 9,393,208 B2)
`IPR2018-01341 (Patent 9,393,208 B2)3
`_________________________
`
`Before TONI R. SCHEINER, MICHELLE N. ANKENBRAND, and
`DEBRA L. DENNETT, Administrative Patent Judges.
`
`DENNETT, Administrative Patent Judge.
`
`ORDER
`Denying Patent Owners’ Motions to Terminate
`37 C.F.R. §§ 42.71(a), 42.72
`
`1 On March 27, 2019, we vacated institution and terminated IPR2017-01995
`(Paper 71), making this motion moot with respect to that case.
`2 Petitioner Dr. Reddy’s Laboratories, Inc. (“Dr. Reddy’s”), from IPR2018-
`00894, was joined as a Petitioner to IPR2017-01995.
`3 We exercise our discretion to issue one Order to be filed in all three cases.
`The parties are not authorized to use this style heading for subsequent papers
`without Board preapproval.
`
`
`
`IPR2017-01995 (Patent 9,220,698 B2)
`IPR2018-00272 (Patent 9,393,208 B2)
`IPR2018-01341 (Patent 9,393,208 B2)
`
`
`
`
`
`
`
`
`
`
`
`
`
`INTRODUCTION
`I.
`On February 10, 2019, pursuant to our prior authorization, Patent
`Owners filed a motion to terminate in each of the above-referenced
`proceedings. IPR2017-01995 (“the 1995 IPR”), Paper 66; IPR2018-00272
`(“the 272 IPR”), Paper 25; IPR2018-01341 (“the 1341 IPR”), Paper 17.4
`Petitioners filed oppositions to each motion on February 22, 2019.
`1995 IPR, Paper 68 (“Opp.”).5
`BACKGROUND
`II.
`According to Patent Owners, litigation involving U.S. Patent No.
`9,220,698 (“the ’698 patent”) commenced in February 2016, and litigation
`involving U.S. Patent No. 9,393,208 (“the ’208 patent”) commenced in
`December 2016, in the U.S. District Court for the District of New Jersey
`(collectively, the “New Jersey Action”). Mot. 2. Petitioner Mylan
`Pharmaceuticals Inc. (“Mylan”) filed a Petition requesting an inter partes
`review of the ’698 patent in August 2017, and filed a Petition requesting an
`inter partes review of the ’208 patent in December 2017. 1995 IPR, Paper
`2; 272 IPR, Paper 2. Between these filings, the court in the New Jersey
`
`
`4 The parties filed substantively similar papers in each proceeding. We refer
`to Patent Owners’ motions collectively as the “Motion” or “Mot.” and
`Petitioners’ oppositions collectively as the “Opposition” or “Opp.” We also
`cite to the Papers and Exhibits filed in the 1995 IPR, unless otherwise
`specified.
`5 Petitioner Dr. Reddy’s Laboratories, Inc. (“Dr. Reddy’s”), who filed in the
`1341 IPR a motion to join the 272 IPR as a petitioner, did not respond to the
`motion to terminate the 1341 IPR, presumably because we have not yet
`determined whether to institute the 1341 IPR or whether to grant
`Dr. Reddy’s joinder motion.
`
`
`
`2
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2017-01995 (Patent 9,220,698 B2)
`IPR2018-00272 (Patent 9,393,208 B2)
`IPR2018-01341 (Patent 9,393,208 B2)
`
`
`Action issued a Markman order construing the term “target,” which is
`recited in the independent claims of both patents, to mean “set as a goal.”
`Ex. 2073, 11.
`We instituted review of the ’698 patent on March 8, 2018, and we
`instituted review of the ’208 patent on June 14, 2018. 1995 IPR, Paper 18;
`272 IPR, Paper 9. In our Institution Decision (“Dec.”), we construed the
`term “target,” as recited in the ’698 and ’208 patents, to mean “have or set
`the goal of obtaining.” Dec. 11–12.6
`On July 2, 2018, Dr. Reddy’s filed its Petition in the 1341 IPR and a
`motion to join the 272 IPR. 1341 IPR, Papers 2, 3. On August 14, 2018, we
`joined Dr. Reddy’s as a Petitioner to the 1995 IPR. Paper 47.
`During this time, the New Jersey Action continued in parallel to our
`proceedings. On August 10, 2018, Mylan and Dr. Reddy’s moved for
`summary judgment in the New Jersey Action, arguing that the claims of the
`’698 and ’208 patents are invalid as indefinite under the district court’s
`claim construction. Ex. 2074.
`On August 28, 2018, then-Patent Owner Pozen Inc. filed a Suggestion
`of Bankruptcy in the 1995 IPR and the 272 IPR. Paper 50. We
`acknowledged the automatic stay under 11 U.S.C. § 362 and suspended all
`deadlines in our proceedings until the bankruptcy court lifted the stay. Paper
`51. The New Jersey Action, however, continued.
`
`
`6 The claims of the ’698 and ’208 patents use the terms “target” as follows:
`“the AM and PM unit dose forms target” or “further target” specified
`pharmacokinetic and pharmacodynamics profiles. See, e.g., Ex. 1001,
`52:26–38 (’698 patent claim 1).
`
`
`
`3
`
`
`
`
`
`
`
`
`
`IPR2017-01995 (Patent 9,220,698 B2)
`IPR2018-00272 (Patent 9,393,208 B2)
`IPR2018-01341 (Patent 9,393,208 B2)
`
`
`On November 19, 2018, the court in the New Jersey Action granted
`Mylan’s and Dr. Reddy’s motion for summary judgment of invalidity,
`holding the claims of the ’698 and ’208 patents invalid as indefinite when
`applying the court’s construction of the term “target.” See Ex. 2075, 10
`(“Because . . . this Court concluded that ‘target’ means ‘set as a goal,’ it is
`not possible to discern what the target clauses are telling you to do or not
`do.”). Patent Owners filed a notice of appeal of that decision to the United
`States Court of Appeals for the Federal Circuit on February 21, 2019.
`Ex. 1056.
`After we lifted the stay of these proceedings, we authorized Patent
`Owners to file a motion to terminate as a result of the district court’s
`granting summary judgment of invalidity.
`III. DISCUSSION
`Patent Owners make essentially two arguments in support of
`termination: (1) Petitioners cannot meet their burden of demonstrating, by a
`preponderance of the evidence, that the challenged claims are unpatentable
`because the court in the New Jersey Action found the claims indefinite; and
`(2) proceeding with the inter partes reviews would not be an effective use of
`the Board’s resources in light of Patent Owners’ appeal of the district court
`decisions to the Federal Circuit. Mot. 1.
`Petitioners respond that the Board has already construed the claims
`and applied the prior art in the decisions to institute (1995 IPR, Paper 18;
`272 IPR, Paper 9). Opp. 5–9. Petitioners also argue that efficiency does not
`weigh in favor of terminating these proceedings. Id. at 9–10.
`
`
`
`
`
`
`
`4
`
`
`
`IPR2017-01995 (Patent 9,220,698 B2)
`IPR2018-00272 (Patent 9,393,208 B2)
`IPR2018-01341 (Patent 9,393,208 B2)
`
`
`For the reasons discussed below, we deny Patent Owners’ motions to
`terminate.
`
`
`
`
`
`
`
`
`
`
`
` Effect of District Court’s Indefiniteness Determination
`In an inter partes review, we are tasked with considering whether
`issued claims are unpatentable only under 35 U.S.C. §§ 102 or 103 on the
`basis of prior art consisting of patents or printed publications. 35 U.S.C.
`§ 311(b). In other words, consideration of indefiniteness under 35 U.S.C.
`§ 112 of issued claims is outside our statutory limits. Id.; see also Cuozzo
`Speed Techs., LLC v. Lee, 136 S. Ct. 2131, 2141–42 (2016) (characterizing
`canceling an issued patent claim for indefiniteness under § 112 in an inter
`partes review proceeding as “shenanigans”).
`In its order granting summary judgment of invalidity on the ground of
`indefiniteness, the court in the New Jersey Action determined that the target
`clauses limit the claims, and focused on the difficulty a potential infringer
`might have in determining what acts constitute infringement. Ex. 2075, 5, 9
`(questioning how a physician would determine the boundary for what he or
`she may legally do without infringing the claims), 10 (explaining that
`applying its construction of the term “target,” there is no discernable
`standard for drawing the line that distinguishes infringing acts from non-
`infringing acts), 14 (holding that the patents fail to teach how to draw the
`line to determine what to do to avoid infringing).
`Our purview is different. See 35 U.S.C. § 311(b). We interpret the
`issued claims and determine whether prior art patents and printed
`publications anticipate the claims or render them obvious. Id. What a prior
`art reference discloses is a question of fact. In re Beattie, 974 F.2d 1309,
`1311 (Fed. Cir. 1992). In determining whether a petitioner has carried its
`5
`
`
`
`
`
`
`
`
`
`
`
`IPR2017-01995 (Patent 9,220,698 B2)
`IPR2018-00272 (Patent 9,393,208 B2)
`IPR2018-01341 (Patent 9,393,208 B2)
`
`
`burden of establishing unpatentability, we need not necessarily determine
`the outer boundaries of a claim in reaching a conclusion as to whether the
`asserted prior art anticipates a claim or renders it obvious. Further, unlike a
`U.S. district court, we do not determine whether the claims comply with
`§ 112, ¶ 2, for infringement purposes. We maintain our focus on the issue of
`patentability based on the evidence before us. And we do not apply our
`claim constructions with a focus on what a potential infringer may or may
`not be able to discern as to whether its actions infringe the challenged
`claims.
`Patent Owners argue that it is inappropriate for us to consider prior art
`challenges where claims are indefinite. Mot. 4–5 (citing Blackberry Corp. v.
`MobileMedia Ideas, LLC, Case IPR2013-00036 (PTAB Mar. 7, 2014)
`(Paper 65); Microsoft Corp. v. IpLearn-Focus, LLC, Case IPR2015-00097
`(PTAB Mar. 26, 2015) (Paper 11)). As we note above, however, we did not
`conclude in the Institution Decisions that the term “target” was unclear or
`failed to delineate the scope of the ’698 and ’208 patent claims with
`reasonable certainty. Rather, we construed the term, applied the asserted
`references, and determined that Petitioner established a reasonable
`likelihood of prevailing on the merits of its patentability challenges.
`Dec. 11–12, 20–29.
`The decisions Patent Owners cite in support of their argument,
`therefore, are inapposite. For example, in Blackberry Corp. v. MobileMedia
`Ideas, LLC, we instituted trial, then terminated the proceeding because the
`independent claims contained a computer-implemented means-plus-function
`element, but the specification failed to disclose a specific algorithm with
`
`
`
`
`
`
`
`6
`
`
`
`
`
`
`
`
`
`IPR2017-01995 (Patent 9,220,698 B2)
`IPR2018-00272 (Patent 9,393,208 B2)
`IPR2018-01341 (Patent 9,393,208 B2)
`
`
`which to program a microprocessor to achieve the claimed function. Case
`IPR2013-00036, slip op. 13, 20 (PTAB Mar. 7, 2014) (Paper 65). We
`rejected Patent Owner’s proposal to conduct the prior art analysis based on
`only the functional recitation of the means-plus-function element, finding
`that “an obviousness determination based on less than all of the claimed
`elements is speculative as to the meaning or scope of the claims.” Id. at 20.
`And in Microsoft Corp. v. IpLearn-Focus, LLC, we held a claim term was
`amenable to two plausible claim interpretations, and, therefore, failed to
`delineate the scope of the invention with reasonable certainty. Case
`IPR2015-00097, slip op. 9 (PTAB Mar. 26, 2015) (Paper 11). Although we
`agree that we have the authority to reconsider a decision to institute and
`subsequently terminate a proceeding, see Medtronic, Inc. v. Robert Bosch
`Healthcare System, Inc., 839 F.3d 1382, 1386 (Fed. Cir. 2016), we find that
`the circumstances noted in Patent Owners’ cited decisions are markedly
`different from the circumstances in the present case.
`Patent Owners contend that Petitioners cannot meet their burden of
`proof that the challenged claims are anticipated by or obvious over the cited
`prior art “because they rely on a construction, which has been accepted in
`this proceeding, that both they and the district court found to be indefinite.”
`Mot. 6. We disagree. Petitioners argue in this proceeding that the broadest
`reasonable interpretation of “target” as used in the challenged claims means
`“with the goal of obtaining,” but they also explain that they presented the
`alternative argument in parallel district court proceedings that the term
`“target” is indefinite. See Paper 2, 16 n.3. As we note above, the court in
`the New Jersey Action construed the term “target” to mean “set as a goal.”
`
`
`
`
`
`
`
`7
`
`
`
`
`
`
`
`
`
`IPR2017-01995 (Patent 9,220,698 B2)
`IPR2018-00272 (Patent 9,393,208 B2)
`IPR2018-01341 (Patent 9,393,208 B2)
`
`
`Ex. 2073, 11. The court, however, ultimately determined that although it
`could construe the term “target,” it could not apply that construction for
`purposes of determining infringement. See Ex. 2075, 9 (“This Court sees no
`way that defining the goals for a method can, without more, inform the
`public of how to act to avoid infringement.”), 10 (“Defendants are correct
`that the patent provides no discernable standard for drawing the line that
`distinguishes infringing acts from noninfringing ones.”).
`Patent Owners’ argument suggests that we are required to agree with
`the district court’s determination that the “target” clauses are indefinite. But
`we are not required to reach the same determinations as the district court.
`See Novartis AG v. Noven Pharms. Inc., 853 F.3d 1289, 1294 (Fed. Cir.
`2017) (explaining that, even on the same record, the Board properly may
`reach a different conclusion than that of a district court). Indeed, we cannot
`reach the same determination as the district court here, as the district court’s
`determination is based on applying its claim construction to determine
`infringement, and we are limited to addressing in an inter partes review
`whether the challenged claims are patentable “on a ground that could be
`raised under section 102 or 103 and only on the basis of prior art consisting
`of patents or printed publications.” 35 U.S.C. § 311(b). We determined that
`Petitioners established a reasonable likelihood that the prior art anticipates or
`renders the claims obvious.
` Use of Judicial Resources
`Patent Owners argue that continuing a trial in these proceedings
`would be a waste of our resources. Mot. 8. Specifically, Patent Owners
`contend that an appeal of the court’s judgment of indefiniteness in the New
`Jersey Action will focus on the construction of the term “target” and the
`8
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2017-01995 (Patent 9,220,698 B2)
`IPR2018-00272 (Patent 9,393,208 B2)
`IPR2018-01341 (Patent 9,393,208 B2)
`
`
`scope of the pharmacokinetic and pharmacodynamic elements of the claims,
`and that such issues are dispositive in this proceeding. Id. Patent Owners
`cite Comtech Mobile Datacom Corp. v. Vehicle IP, LLC, Case IPR2018-
`00531 (PTAB July 20, 2018) (Paper 9), as presenting a situation similar to
`that before us. Mot. 8–9.
`In Comtech Mobile, we exercised discretion under 35 U.S.C. § 314(a)
`to deny institution of review. Case IPR2018-00531, Paper 9, 2. There,
`district court litigation on the challenged patent, ongoing for nine years at
`the time, was on its second appeal to the Federal Circuit over claim
`construction issues. Id. at 3. In particular, construction of a certain claim
`term was at issue in the pending Federal Circuit appeal and also potentially
`dispositive in the inter partes review, if instituted. Id. at 12. We determined
`that, were we to construe the term, we would be deciding (under the same
`standard) a disputed legal issue that was already before the Federal Circuit
`for resolution. Id. Also weighing in favor of denying an inter partes review,
`included the lengthy litigation history of the challenged patent against
`parties other than the petitioner, the patent owner’s offer of a covenant not to
`sue the petitioner or its customers for infringement of the challenged patent,
`and the lack of litigation (and, therefore, any time bar under 35 U.S.C.
`§ 315(b)) against the petitioner. Id. at 13.
`The proceedings before us are distinguishable from Comtech Mobile.
`First, we are not faced with similar circumstances regarding the litigation
`history of the challenged patents, the lack of copending district court
`litigation, or a patent owner’s covenant not to sue. Second, and more
`importantly, we already have instituted inter partes reviews in the 1995 IPR
`
`
`
`
`
`
`
`9
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2017-01995 (Patent 9,220,698 B2)
`IPR2018-00272 (Patent 9,393,208 B2)
`IPR2018-01341 (Patent 9,393,208 B2)
`
`
`and the 272 IPR. See, e.g., 1995 IPR, Paper 18; 272 IPR, Paper 9.7 But for
`the stay of these cases during Patent Owner Pozen’s bankruptcy proceeding,
`we would have issued our Final Written Decision in the 1995 IPR on or
`before March 8, 2019. See Paper 70. Now that the bankruptcy stay is lifted,
`we will convene an oral hearing for both cases on June 14, 2019 (if the
`parties request oral hearing), and we will issue our Final Written Decision in
`the both IPRs on or before September 8, 2019. Papers 67, 70. These
`proceedings, therefore, are not in their early stages and, contrary to Patent
`Owners’ position, we find that terminating these inter partes reviews at this
`time would waste the significant resources that the parties and the Board
`already have expended on the proceedings. In addition, Patent Owners only
`recently filed a notice of appeal of the decision in the New Jersey Action
`(see Ex. 1056). Thus, the Federal Circuit’s decision on the appeal is
`unlikely to issue until after we issue the Final Written Decisions in these
`proceedings.
`
`IV. CONCLUSION
`Having considered the Motions to Terminate and Oppositions, and the
`evidence of record, we deny the motions. We deny the motions without
`prejudice, however, should the Federal Circuit decide Patent Owners’ appeal
`before we issue the Final Written Decisions in these proceedings.
`
`
`
`
`
`7 Although we have not yet instituted review in the 1341 IPR, as we note
`above, Dr. Reddy’s seeks to join the 272 IPR. Should we grant Dr. Reddy’s
`motion for joinder, the 1314 IPR will proceed along the same schedule as
`the 272 IPR.
`
`
`
`10
`
`
`
`IPR2017-01995 (Patent 9,220,698 B2)
`IPR2018-00272 (Patent 9,393,208 B2)
`IPR2018-01341 (Patent 9,393,208 B2)
`
`
`
`
`
`
`
`
`
`
`
`
`
`V. ORDER
`In consideration of the foregoing, it is hereby:
`ORDERED that the Motion to Terminate IPR2017-01995 is dismissed
`as moot due to termination of the proceeding;
`ORDERED that the Motions to Terminate IPR2018-00272 and
`IPR2018-01341 are denied without prejudice to reconsideration, should the
`Federal Circuit decide Patent Owners’ appeal before we issue the Final
`Written Decisions in these proceedings.
`
`
`
`
`
`11
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2017-01995 (Patent 9,220,698 B2)
`IPR2018-00272 (Patent 9,393,208 B2)
`IPR2018-01341 (Patent 9,393,208 B2)
`
`
`PETITIONER:
`
`Brandon White
`white-ptab@perkinscoie.com
`
`Emily Greb
`greb-ptab@perkinscoie.com
`
`Alan Pollack
`apollack@buddlarner.com
`
`Louis Weinstein
`lweinstein@buddlarner.com
`
`
`PATENT OWNER:
`
`Thomas Blinka
`tblinka@cooley.com
`
`Margaret Sampson
`margaret.sampson@bakerbotts.com
`
`
`
`
`12
`
`